Creative Biogene Expands Antibody Purification Platform to Support Biotechnology Innovation

Creative Biogene's expanded antibody purification platform provides a streamlined purification workflow for producing high-yield, high-purity antibodies from scalable and customizable protocols. The platform refines antibody purification strategies from various expression sources and is available for companies and research institutions to aid in the growing need for consistent and efficient antibody preparations. This expansion demonstrates the company's commitment to empowering biotechnology research with high-quality, accessible technology.

The platform features a robust purification workflow incorporating capture, intermediate, and polishing steps. Protein A/G/L resins are utilized for Fc-binding antibodies, while ion exchange chromatography is available for charge-based purification and size exclusion chromatography for removing aggregates, ensuring final antibody purity of greater than 95%. The platform also features orthogonal and complementary processes, such as hydrophobic interaction chromatography, multimodal, and buffer exchange. Complementary quality control services include SDS-PAGE, SEC-HPLC, and endotoxin testing, with results delivered in a Certificate of Analysis report.

A comprehensive range of equipment supports the platform, with chromatography columns that are compact and easy to operate. Process chromatography systems are available at laboratory and pilot scales, allowing customizable system design. Buffer dilution and conditioning systems enable precise formulation while reducing resource use. Filtration systems, including tangential flow, depth filtration, and single-use options, ensure fast turnaround between runs. These integrated assets provide a complete and flexible solution for antibody purification needs.

The platform is designed for various biotechnology applications, where antibody materials can be used in antibody candidate development programs, assay optimization, production of kit components, and as research reagents. The evaluation of the platform clearly indicated that its main value comes from the well-balanced throughput and reproducibility. The platform has been optimized to provide consistent results across various scales and antibody targets, allowing researchers to streamline their work effectively.

Creative Biogene is looking ahead to continue improving the system with more automation features and increased scalability. Through future integration and the continued refinement of purification protocols and scalable design, the company will continue to provide comprehensive solutions for current and future research needs in the biotechnology sector.